Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Avistone Closes $140 million Series B Round for Precision Medicine Oncology Portfolio

publication date: Jan 5, 2024

Beijing Avistone Biotech completed a $140 million Series B financing to advance its portfolio of innovative precision medicine oncology candidates. In late 2021, Avistone received a $200 million strategic investment led by Vivo Capital while also merging with Beijing’s Pearl Biotech. The portfolio of the two companies included Avistone's lead drug, a c-Met inhibitor in late-stage clinical development for genetically-defined NSCLC and glioblastoma patients. Avistone in-licensed the drug from Apollomics of California. The new Series B financing was led by SDIC CS Capital and IDG Capital, with Yanchuang Capital and Cathay Capital participating. An existing shareholder, Bain Capital, also made an investment. More details...

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital